These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32553625)

  • 21. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis.
    Wang W; Wu C; Tian B; Liu X; Zhai Z; Qu X; Jiang C; Ouyang Z; Mao Y; Tang T; Qin A; Zhu Z
    Int J Mol Sci; 2014 Nov; 15(12):21913-34. PubMed ID: 25464380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenethyl isothiocyanate suppresses receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages.
    Murakami A; Song M; Ohigashi H
    Biofactors; 2007; 30(1):1-11. PubMed ID: 18198396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
    Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
    Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.
    Sakai E; Shimada-Sugawara M; Yamaguchi Y; Sakamoto H; Fumimoto R; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    J Pharmacol Sci; 2013; 121(4):288-98. PubMed ID: 23538677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways.
    Nie S; Xu J; Zhang C; Xu C; Liu M; Yu D
    Biochem Biophys Res Commun; 2016 Jan; 470(1):61-67. PubMed ID: 26740180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poria cocos polysaccharide attenuates RANKL-induced osteoclastogenesis by suppressing NFATc1 activity and phosphorylation of ERK and STAT3.
    Song D; Cao Z; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Guo C; Dong S; Xu J
    Arch Biochem Biophys; 2018 Jun; 647():76-83. PubMed ID: 29678628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium-containing crystals enhance receptor activator of nuclear factor κB ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways.
    Chang CC; Tsai YH; Liu Y; Lin SY; Liang YC
    Rheumatology (Oxford); 2015 Oct; 54(10):1913-22. PubMed ID: 25998451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
    Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
    J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycyrrhizin Suppresses RANKL-Induced Osteoclastogenesis and Oxidative Stress Through Inhibiting NF-κB and MAPK and Activating AMPK/Nrf2.
    Li Z; Chen C; Zhu X; Li Y; Yu R; Xu W
    Calcif Tissue Int; 2018 Sep; 103(3):324-337. PubMed ID: 29721581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes.
    Hirata K; Taki H; Shinoda K; Hounoki H; Miyahara T; Tobe K; Ogawa H; Mori H; Sugiyama E
    Biol Pharm Bull; 2010; 33(1):133-7. PubMed ID: 20045951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ampelopsis brevipedunculata extract prevents bone loss by inhibiting osteoclastogenesis in vitro and in vivo.
    Kim JY; Park SH; Oh HM; Kwak SC; Baek JM; Lee MS; Rho MC; Oh J
    Molecules; 2014 Nov; 19(11):18465-78. PubMed ID: 25397737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
    Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
    FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.